https://www.selleckchem.com/pr....oducts/kynurenic-aci
precisiondosing.de. Although the network covers only a fraction of possible simvastatin DDGIs, it provides guidance on how PBPK modeling could be used to individualize pharmacotherapy in the future. Furthermore, the network model is easily extendable to cover additional DDGIs. Overall, the presented work is a first step toward a vision on comprehensive precision dosing based on PBPK models in daily clinical practice, where it could drastically reduce the risk of ADRs.Warfarin remains the oral anticoagulant of choice in sub-Sahara
Like
Comment
Share
